Biota Pharma acquires Anaconda Pharma including lead product AP 611074 for condyloma

Biota Pharmaceuticals announced that it has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, France. Anaconda Pharma's lead candidate is AP 611074, a patented, direct-acting antiviral in development for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis (RRP), both of which are caused by human papillomavirus (HPV) types 6 and 11. Anaconda Pharma has successfully completed a Phase IIa clinical trial of AP 611074 5% gel demonstrating biological activity with a significant reduction in the surface area of condyloma while exhibiting favourable local skin tolerability.